About 5% of nonmedullary thyroid cancer is familial. These familial nonmedullary thyroid cancer cases are characterized by an earlier age of onset, more aggressive phenotype, and in some families a high propensity to benign thyroid disease. Little is known about the genes conferring predisposition to nonmedullary thyroid cancer. Three loci have been identified through genetic linkage: MNG1 on 14q32, TCO1 on 19p13.2, and fPTC on 1p21. In addition to these putative genes, a number of loci represent candidate familial nonmedullary thyroid cancer predisposition genes by virtue of their involvement in sporadic disease (TRKA), their role in benign disease (TSHR), and because they underlie syndromes with a risk of nonmedullary thyroid cancer (PTEN 
About 5% of nonmedullary thyroid cancer is familial. These familial nonmedullary thyroid cancer cases are characterized by an earlier age of onset, more aggressive phenotype, and in some families a high propensity to benign thyroid disease. Little is known about the genes conferring predisposition to nonmedullary thyroid cancer. Three loci have been identified through genetic linkage: MNG1 on 14q32, TCO1 on 19p13.2, and fPTC on 1p21. In addition to these putative genes, a number of loci represent candidate familial nonmedullary thyroid cancer predisposition genes by virtue of their involvement in sporadic disease (TRKA), their role in benign disease (TSHR), and because they underlie syndromes with a risk of nonmedullary thyroid cancer (PTEN). To evaluate the roles of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer, we have carried out a comprehensive mutation and linkage analysis of these genes in 22 families. One family was linked to chromosome 19q13. 2 (3, 4) studies indicates that a subset is familial. The pattern of inheritance in many reported families is compatible with an autosomal dominant model with incomplete penetrance (1, 2) . Characteristics of familial NMTC (FNMTC) include an earlier age of onset, more aggressive phenotype-multifocal disease, and more frequent relapses (1, 2) . In some families there is evidence that genetic susceptibility to NMTC and benign thyroid disease, typically multinodular goiter (MNG), are related (1). Three FNMTC loci have been mapped by genetic linkage analysis using single, multiple case families. These include MNG1 on chromosome 14q32 (5), TCO1 on chromosome 19p13.2 (6), and fPTC on chromosome 1p21 (7) . In addition to these putative genes, a number of loci represent candidate FNMTC predisposition genes by virtue of their involvement in sporadic disease (TRKA) (8) , their role in nonmalignant thyroid disease (TSHR) (9) , and because they underlie a syndrome associated with a risk of NMTC (PTEN causing Cowden's syndrome) (10) .
To evaluate the contributions of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA to familial NMTC we undertook a linkage and mutation analysis of these loci in 22 FNMTC families.
Subjects and Methods
Twenty-two families with two or more members affected with NMTC were studied ( Table 1 ). The average age at diagnosis of NMTC was 39.7 yr (sd, 15.2 yr), with a male to female ratio of 1:4.7. None of the affected individuals had clinical features indicative of familial adenomatous polyposis or had features meeting the operational criteria of the International Cowden Consortium (11) for a diagnosis of Cowden's syndrome. The relevant institutional review boards approved the study. Blood samples were collected from family members, and DNA was isolated using a standard sucrose lysis protocol.
The search for germline mutations in PTEN, TSHR, and TRKA was performed using conformational sensitive gel electrophoresis (12) . A combination of published [TSHR (13) and PTEN (14) ] and newly designed oligonucleotides (TRKA) was used to amplify each exon in the PCR. Oligonucleotide sequences for forward and reverse TRKA primers (5Ј33Ј) were as follows: exon 1: ggggcgtcagagagtagg, caaacaagcagcgagtcc; exon 2, gcctgagccctgtgactc, gccctccctgacctcctg; exon 3, ctgagggactgggagaag, ggagaatggtgaggtgac; exon 4, tcctcccctcctcattc, tccaacagacccaagtg; exon 5, gccctctccttgactctg, ccccttacaccacctc; exon 6, ggagcagccccgcagtag, ctctttccccatctttgt; exon 7, ggctctccaaagacttca, tgacaagaccccaggact; exon 8, cctgacctcctgctgttg, tcccgaaccaggcactc; exon 9, gtaggcaggggactcact, atctccctgctctgacca; exon 10, aaaatggcttactacagg, aaagccaggagaacagac; exon 11, cggctgtgtctcctctct, gcccttgacccagcatag; exon 12, agtggggctaccgtctga, cccactctgtccagatgt; exon 13, gacatggctggataccgg, tctccccttggtttgaa; exon 14, ccctctccttttcttgtt, aaggcgttggggacaaag; exon 15, cctggaattgatgcagtg, aggccagcaagaggtgac; and exon 16, gtgggctttctcctctgt, cccagtattccggctaac. Samples with band shifts were sequenced after reamplification of the appropriate exon from genomic DNA in the PCR. Purified PCR products were sequenced using the ABI Ready Reaction Dye Terminator Cycle Sequencing Kit and an ABI 377 Prism Abbreviations: FNMTC, Familial nonmedullary thyroid cancer; MNG, multinodular goiter; NMTC, nonmedullary thyroid cancer; NPL, nonparametric linkage; PTC, papillary thyroid cancer.
sequencer. Families were included in a linkage analysis of PTEN, TRKA, MNG1, TSHR, TCO, and fPTC if DNA was available from two or more affected individuals who were not simply parent and child. Fluorescently labeled microsatellite markers situated in or near the TSHR (D14S61, D14S606, D14S68), PTEN (D10S201, D10S573, D10S541), and TRKA (D1S498, D1S1595, D1S2635) genes and linked markers in the MNG1 (D14S498, D14S1030, D14S267), TCO1 (D19S391, D19S916, D19S413, D19S865, D19S568), and fPTC (D1S2881, D1S514, D1S498, D1S305) regions were used to genotype family members. Dye-labeled PCR products were detected on ABI 377 DNA sequencers and analyzed using Genescan and Genotyper software (Applied Biosystems, Cheshire, UK). In the absence of a precise mode of inheritance for NMTC, the gene frequency, penetrance, and phenocopy rate of a dominant model were constrained to fit the observed familial relative risk of thyroid cancer of 8.0 (4) and a population prevalence of 0.002 (15) (0.001, 0.018, and 0.0016, respectively). An estimation of the proportion of families linked to each locus was obtained by a test of heterogeneity. Nonparametric linkage (NPL) scores were also determined. Both parametric and nonparametric multipoint analyses were performed using the GENEHUNTER program (16) . Distances between markers were obtained from Genetic Location Database (http://cedar.genetics. soton.ac.uk/public_html/). Marker allele frequencies were derived from observed relative frequencies.
Results
All affected family members with either MNG or NMTC in the 22 families were screened for constitutional mutations in PTEN, TSHR, and TRKA. A nonsense polymorphism in TSHR was detected (C3 T, Asn 168 Asn), but no pathogenic mutations (novel, missense, or truncating) in PTEN, TSHR, or TRKA were identified. All 21 potentially informative families were used in the linkage study of PTEN, TSHR, TRKA, TCO1, MNG1, and fPTC loci. Linkage analysis was undertaken imposing 2 criteria for defining affection status. Firstly, only individuals with NMTC were classed as affected; family members with benign thyroid disease were considered of unknown phenotype. Under this criteria, analysis was undertaken using both parametric and nonparametric approaches. Secondly, individuals were considered affected if they had either NMTC or MNG. Under this criteria analysis was only performed using a nonparametric approach. Table  2 shows the multipoint LOD and NPL scores for all of the families under both models. LOD scores were negative for TSHR, PTEN, MNG1, and TRKA1. Only at the TCO1 locus was there any evidence for linkage. This was principally seen in family 1680 (Fig. 1) , which showed cosegregation of the chromosome19p13.2 marker haplotype defined by D19S391-D19S916-D19S413-D19S865-D19S586 and NMTC. The LOD score in this family is 1.54, and the NPL score is 4.33 (P ϭ 0.03). 
Discussion
Although about 5% of NMTC patients have a family history of the disease, comparatively little is known about the genes underlying familial forms of the disease (1). In 1997 we mapped the gene for multinodular goiter (MNG1) to chromosome 14q31 in a Canadian family segregating 18 cases of MNG and 2 cases of papillary thyroid cancer (PTC) (5). Subsequently, a gene predisposing to an unusual form of thyroid tumor with cell oxyphilia (TCO1) was mapped to chromosome 19p13.2 in a French kindred containing 6 cases of MNG and 3 cases of PTC (6) . More recently, the putative gene fPTC was mapped in a family with 5 cases of papillary thyroid cancer, 3 cases of thyroid nodules, and 2 cases of papillary renal neoplasia to chromosome 1q21 (7) .
None of the families we examined in this study showed significant linkage to the putative FNMTC thyroid cancer genes MNG1 or fPTC. Two other reports have found that the majority of FNMTC kindreds are not linked to MNG1 (5, 17) . One of the families did, however, show linkage of NMTC to chromosome 19p13.2, providing independent confirmation of TCO1 as a NMTC predisposition locus. In contrast to the family previously linked to TCO1 (6), the thyroid cancers in our family were papillary rather than Hurthle cell.
We evaluated TSHR as a candidate gene for FNMTC, as it is implicated in benign thyroid disease, and activating mutations may affect thyroid cellular differentiation (9, 18, 19) . There is, however, no evidence from this study that mutations in TSHR are a cause of FNMTC. TRKA represents a candidate susceptibility locus because of its involvement in sporadic cancer and its localization to the fPTC locus. There was, however, no evidence from this study that germline mutations in TRKA cause FNMTC. There was also no evidence from our study to indicate that mutations in PTEN cause NMTC outside the context of Cowden's syndrome.
This study in addition to other reports indicate that FNMTC is genetically heterogeneous, and the majority of NMTC kindreds are unlinked to the putative predisposition genes MNG1 (5), TCO1 (6), and fPTC (7). This has considerable implications for the localization of further FNMTC predisposition genes, as genetic heterogeneity severely reduces the power of linkage in a genomic search. The three putative FMTC predisposition loci that have been detected to date, MNG1, TCO1, and fPTC, were located in single, multiple case families, sufficiently large to detect linkage in isolation. Most FNMTC families encountered are relatively small. In the context of allelic heterogeneity, the detection of additional novel FNMTC genes may be problematic. It is, however, increasingly clear that FNMTC can be divided into a number of groups on the basis of pathology and clinical features. Multiple tumors of the same histological type within a family are compatible with a specific germline mutation. Subcategorization of NMTC families on the basis of phenotype therefore provides a powerful strategy for enhancing the power of future linkage studies, especially if the involvement of known genes can be excluded. 
